Top 5 Canadian Biotech Stocks of 2025
Biotech is a dynamic industry that is driving scientific advances and innovation in healthcare. In Canada, the biotech sector is home to companies pursuing cutting-edge therapies and medical technologies.
According to Grandview Research, the global biotech market is expected to grow at a compound annual growth rate of 13.96 percent between 2024 and 2030 to reach a value of US$3.08 trillion.
Here the Investing News Network profiles the five best-performing Canadian biotech stocks on the TSX, TSXV and CSE, based on year-on-year gains. Data on these companies was collected on July 18, 2025, using TradingView’s stock screener, and companies with market caps above C$10 million at that time were considered.
Read on to learn what’s been driving these Canadian biotech firms.
1. Bright Minds Biosciences (CSE:DRUG)
Year-on-year gain: 2,290 percent
Market cap: C$243.73 million
Share price: C$34.41
Bright Minds Biosciences is focused on developing novel treatments for neuropsychiatric disorders and pain.
Its portfolio consists of serotonin agonists designed to target neurocircuit abnormalities that make disorders like epilepsy, post-traumatic stress disorder and depression difficult to treat. The company’s drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing their side effects, thereby creating superior drugs to first-generation compounds such as psilocybin.
Bright Minds’ BMB-101, an agonist targeting the 5-HT2C receptor, will target classic absence epilepsy and developmental epileptic encephalopathy. An evaluation of Phase II trials done in collaboration with Firefly Neuroscience (NASDAQ:AIFF) determined that BMB-101 stopped seizures in a mouse model of epilepsy, suggesting it could be a vital new treatment.
In October 2024, Bright Minds surged nearly 1,500 percent in a single session after global pharma firm H. Lundbeck announced plans to acquire Longboard Pharmaceuticals, which also has a 5-HT2C agonist in its pipeline.
In March of this year, Bright Minds added five world-renowned leaders in epilepsy research to its scientific advisory board.
Year-on-year gain: 170 percent
Market cap: C$20.44 million
Share price: C$0.14
Hemostemix is a clinical-stage biotech company focused on developing autologous stem cell therapies, an approach that uses a patient’s own cells to theoretically enhance safety and efficacy. Its main product, ACP-01, is a cell therapy derived from a patient’s blood to promote tissue repair and regeneration in areas affected by disease.
The company announced its first advanced sales orders for ACP-01 on January 29 and has been working to expand internationally and attract new investment.
In July, Hemostemix reported that the unanimous passing of Senate Bill 1768 in Florida, US, means it can begin commercial ACP-01 treatments for ischemic pain in the state in Q4.
The bill…
Read More: Top 5 Canadian Biotech Stocks of 2025